RETA - レアタ・ファ―マシュ―ティカルズ (Reata Pharmaceuticals Inc.) レアタ・ファ―マシュ―ティカルズ

 RETAのチャート


 RETAの企業情報

symbol RETA
会社名 Reata Pharmaceuticals Inc (レアタ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 レアタ・ファーマスーティカルズ(Reata Pharmaceuticals Inc.)は臨床段階のバイオ医薬品会社である。同社は製品候補の識別・開発・商品化に従事する。製品候補はミトコンドリア機能、酸化ストレス及び炎症生物学に関与する調節タンパク質の活性調節を含み、深刻で生命を脅かす疾患の患者の医療ニーズを満たす。同社の主力製品候補には結合組織疾患(CTD-PAH)に関連する肺動脈高血圧症(PAH)の第III相試験で研究されるバルドキソロンメチル、 フリードライヒ運動失調症、ミトコンドリア・ミオパチー症を含む複数の疾患の治療用フェーズⅡ臨床開発中の肺高血圧症(PH)、フリードライヒ運動失調症、ミトコンドリアミオパチー及び転移性黒色腫を含む疾患の治療用第II相臨床開発のOmaveloxoloneを含む。   レアタ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床ステ―ジで、酸化性ストレスと炎症に関連するタンパク質の活性を調整する薬剤を開発・商業化することに従事する。薬剤候補の「Bardoxoloneメチル」と「Omaveloxolone」は酸化防止剤炎症モジュレ―タからなる。本社はテキサス州ア―ビング。   Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
本社所在地 2801 Gateway Drive Suite 150 Irving TX 75063 USA
代表者氏名 J. Warren Huff J.ウォーレンハフ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 972-865-2206
設立年月日 2002年
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 93人
url www.reatapharma.com
nasdaq_url https://www.nasdaq.com/symbol/reta
adr_tso
EBITDA EBITDA(百万ドル) -50.50300
終値(lastsale) 66.97
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 1803.745
売上高 売上高(百万ドル) 62.48400
企業価値(EV) 企業価値(EV)(百万ドル) 1743.66
当期純利益 当期純利益(百万ドル) -53.11500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Reata Pharmaceuticals Inc revenues increased 56% to $40M. Net loss increased 29% to $24.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 37% to $42.9M (expense) General and administrative - Balancing v increase of 56% to $14.2M (expense).

 RETAのテクニカル分析


 RETAのニュース

   3 Monster Growth Stocks Racing to New Highs  2019/12/15 10:59:52 Nasdaq
As we make our way into the new decade, we’re bound to see some changes take place. However, what’s one constant ready to stand the test of time? Investors seeking out growth. It’s a tried and true fact that potential growth pulls investor focus in as significant gains can translate to massive returns. Having said that, the Wall Street veterans point out that a true monster growth name isn’t just set to make moves in the short-term. Rather, this status can only be earned by stocks racing to new highs through 2020 and beyond. With this in mind, we suited up and set out on our own hunt for the investment opportunities with strong long-term growth narratives. Using the Stock Screener tool from TipRanks, we were able to pinpoint 3 Buy-rated tickers that each boast huge upside potential from current levels. Here’s the lowdown. Reata Pharmaceuticals Inc. ( RETA ) Reata Pharmaceuticals develops innovative treatments for severe life-threatening diseases that currently don’t have any approved or effective therapy available.
   Stocks making the biggest moves after hours: DXC Technology, Reata Pharmaceuticals and Grocery Outlet  2019/11/11 23:33:31 CNBC
See which stocks are posting big moves after the bell on Monday.
   Reata Pharma kidney drug meets study goals, stock halted  2019/11/11 21:23:00 MarketWatch
Reata Pharmaceuticals Inc. shares were halted in the extended session Monday as the biotech drug developer reported positive results from a late-stage kidney…
   Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q3 Earnings Expected to Decline  2019/10/30 14:33:38 Zacks Investment Research
Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study  2019/10/29 11:32:34 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive clinical readout for triple combo lung cancer drug) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cabaletta Bio Inc (NASDAQ: CABA ) (went public Oct. 25) ESSA Pharma Inc (NASDAQ: EPIX ) IGM Biosciences Inc (NASDAQ: IGMS ) Novo Nordisk A/S (NYSE: NVO ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) (reacted to a positive clinical readout) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 28.) Agile Therapeutics Inc (NASDAQ: AGRX ) (reported negative comments from FDA staff in the briefing document posted ahead of Twirla Adcom meeting) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Endologix, Inc. (NASDAQ: ELGX (FDA issued a safety communication to physicians and patients regarding Endologix AFX endovascular grafts) Hoth Therapeutics Inc (NASDAQ: HOTH ) KemPharm Inc (NASDAQ: KMPH ) Miragen Therapeutics Inc (NASDAQ: MGEN ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) Myovant Sciences Ltd (NYSE: MYOV ) Orgenesis Inc (NASDAQ: ORGS ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) Stocks In Focus Mirati's KRAS Inhibitor Shows Tumor Shrinkage Mirati Therapeutics Inc (NASDAQ: MRTX ) announced the first Phase 1/2 trial results for MRTX849, an investigational KRAS G12C inhibitor, in patients with solid tumors expressing KRAS G12C mutations.
   3 Monster Growth Stocks Racing to New Highs  2019/12/15 10:59:52 Nasdaq
As we make our way into the new decade, we’re bound to see some changes take place. However, what’s one constant ready to stand the test of time? Investors seeking out growth. It’s a tried and true fact that potential growth pulls investor focus in as significant gains can translate to massive returns. Having said that, the Wall Street veterans point out that a true monster growth name isn’t just set to make moves in the short-term. Rather, this status can only be earned by stocks racing to new highs through 2020 and beyond. With this in mind, we suited up and set out on our own hunt for the investment opportunities with strong long-term growth narratives. Using the Stock Screener tool from TipRanks, we were able to pinpoint 3 Buy-rated tickers that each boast huge upside potential from current levels. Here’s the lowdown. Reata Pharmaceuticals Inc. ( RETA ) Reata Pharmaceuticals develops innovative treatments for severe life-threatening diseases that currently don’t have any approved or effective therapy available.
   Stocks making the biggest moves after hours: DXC Technology, Reata Pharmaceuticals and Grocery Outlet  2019/11/11 23:33:31 CNBC
See which stocks are posting big moves after the bell on Monday.
   Reata Pharma kidney drug meets study goals, stock halted  2019/11/11 21:23:00 MarketWatch
Reata Pharmaceuticals Inc. shares were halted in the extended session Monday as the biotech drug developer reported positive results from a late-stage kidney…
   Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q3 Earnings Expected to Decline  2019/10/30 14:33:38 Zacks Investment Research
Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study  2019/10/29 11:32:34 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive clinical readout for triple combo lung cancer drug) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cabaletta Bio Inc (NASDAQ: CABA ) (went public Oct. 25) ESSA Pharma Inc (NASDAQ: EPIX ) IGM Biosciences Inc (NASDAQ: IGMS ) Novo Nordisk A/S (NYSE: NVO ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) (reacted to a positive clinical readout) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 28.) Agile Therapeutics Inc (NASDAQ: AGRX ) (reported negative comments from FDA staff in the briefing document posted ahead of Twirla Adcom meeting) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Endologix, Inc. (NASDAQ: ELGX (FDA issued a safety communication to physicians and patients regarding Endologix AFX endovascular grafts) Hoth Therapeutics Inc (NASDAQ: HOTH ) KemPharm Inc (NASDAQ: KMPH ) Miragen Therapeutics Inc (NASDAQ: MGEN ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) Myovant Sciences Ltd (NYSE: MYOV ) Orgenesis Inc (NASDAQ: ORGS ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) Stocks In Focus Mirati's KRAS Inhibitor Shows Tumor Shrinkage Mirati Therapeutics Inc (NASDAQ: MRTX ) announced the first Phase 1/2 trial results for MRTX849, an investigational KRAS G12C inhibitor, in patients with solid tumors expressing KRAS G12C mutations.
   3 Monster Growth Stocks Racing to New Highs  2019/12/15 10:59:52 Nasdaq
As we make our way into the new decade, we’re bound to see some changes take place. However, what’s one constant ready to stand the test of time? Investors seeking out growth. It’s a tried and true fact that potential growth pulls investor focus in as significant gains can translate to massive returns. Having said that, the Wall Street veterans point out that a true monster growth name isn’t just set to make moves in the short-term. Rather, this status can only be earned by stocks racing to new highs through 2020 and beyond. With this in mind, we suited up and set out on our own hunt for the investment opportunities with strong long-term growth narratives. Using the Stock Screener tool from TipRanks, we were able to pinpoint 3 Buy-rated tickers that each boast huge upside potential from current levels. Here’s the lowdown. Reata Pharmaceuticals Inc. ( RETA ) Reata Pharmaceuticals develops innovative treatments for severe life-threatening diseases that currently don’t have any approved or effective therapy available.
   Stocks making the biggest moves after hours: DXC Technology, Reata Pharmaceuticals and Grocery Outlet  2019/11/11 23:33:31 CNBC
See which stocks are posting big moves after the bell on Monday.
   Reata Pharma kidney drug meets study goals, stock halted  2019/11/11 21:23:00 MarketWatch
Reata Pharmaceuticals Inc. shares were halted in the extended session Monday as the biotech drug developer reported positive results from a late-stage kidney…
   Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q3 Earnings Expected to Decline  2019/10/30 14:33:38 Zacks Investment Research
Reata Pharmaceuticals, Inc. (RETA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study  2019/10/29 11:32:34 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive clinical readout for triple combo lung cancer drug) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cabaletta Bio Inc (NASDAQ: CABA ) (went public Oct. 25) ESSA Pharma Inc (NASDAQ: EPIX ) IGM Biosciences Inc (NASDAQ: IGMS ) Novo Nordisk A/S (NYSE: NVO ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) (reacted to a positive clinical readout) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 28.) Agile Therapeutics Inc (NASDAQ: AGRX ) (reported negative comments from FDA staff in the briefing document posted ahead of Twirla Adcom meeting) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Endologix, Inc. (NASDAQ: ELGX (FDA issued a safety communication to physicians and patients regarding Endologix AFX endovascular grafts) Hoth Therapeutics Inc (NASDAQ: HOTH ) KemPharm Inc (NASDAQ: KMPH ) Miragen Therapeutics Inc (NASDAQ: MGEN ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) Myovant Sciences Ltd (NYSE: MYOV ) Orgenesis Inc (NASDAQ: ORGS ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) Stocks In Focus Mirati's KRAS Inhibitor Shows Tumor Shrinkage Mirati Therapeutics Inc (NASDAQ: MRTX ) announced the first Phase 1/2 trial results for MRTX849, an investigational KRAS G12C inhibitor, in patients with solid tumors expressing KRAS G12C mutations.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 レアタ・ファ―マシュ―ティカルズ RETA Reata Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)